FDA to review use of asthma drugs in children

Share this article:

The FDA is recommending an additional safety review of  GlaxoSmithKline's Serevent and Advair and Novartis' Foradil in children.

An advisory panel of pediatricians is scheduled to discuss side effects of the asthma medications at a meeting on Nov. 27.

The FDA strengthened warning labels for the drugs nearly two years ago to limit use to patients who don't benefit from other medications.

“There is no available pediatric data to indicate that the increased risk of asthma death and life-threatening exacerbations observed in adults does not also apply to children,” the FDA wrote in a report posted on its Web site.

The review didn't identify any adverse reactions unique to children but did imply that Serevent may have more risks than benefits for young users. 

Global sales for Serevent and Advair rose 12% to $6.13 billion in 2006, making them the second best-selling medicines behind Pfizer's $12 billion-seller, the cholesterol drug Lipitor.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...